Abstract: The present disclosure relates to an in-silico analysis for inhibitors of Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2). The in-silico screening of Kobophenol A confirmed the effective binding at two positions, firstly at ACE2/Spike interface and secondly at the hydrophobic pocket by destabilizing the complex formation. Kobophenol A inhibited the cell death caused by viral infection without inducing cell toxicity in the absence of viral infection. The molecular dynamics of Kobophenol A indicated the stability of binding of Kobophenol A through hydrogen bond and stabilized at Y495 and K353 with an average distance of 2.95 ?. The binding affinity of Kobophenol A to the ACE2/Spike interface region and the ACE2 hydrophobic pocket is computed to be ?19.0±4.3 and ?24.9±6.9 kcal/mol respectively. Kobophenol A is useful as a potential drug for treatment of COVID-19.